Current Report Filing (8-k)
05 Novembre 2021 - 7:00PM
Edgar (US Regulatory)
0001533743
false
0001533743
2021-11-03
2021-11-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 3, 2021
PROCESSA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-39531
|
|
45-1539785
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
7380
Coca Cola Drive, Suite 106, Hanover, Maryland
|
|
21076
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (443) 776-3133
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.0001 par value per share
|
|
PCSA
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07 - Submission of Matters to a Vote of Security Holders.
A
total of 15,604,605 shares of common stock were entitled to vote as of September 13, 2021, the record date for the Special Meeting. There
were 11,042,376 shares of common stock present in person or represented by proxy at the Annual Meeting, at which the stockholders were
asked to vote on two proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted
upon by the stockholders, and the final voting results of each such proposal.
Proposal
No. 1: Approval of an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to increase
the number of authorized shares of common stock from 30,000,000 shares to 50,000,000 shares. The votes cast were as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
10,857,914
|
|
183,334
|
|
1,128
|
|
0
|
Proposal
No. 2: Approve an adjournment of the Special Meeting, if the Board of Directors determines it to be necessary or appropriate,
if a quorum is present, solicit additional proxies if there are not sufficient votes in favor of Proposal 1. The votes cast were as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
10,785,919
|
|
249,851
|
|
6,606
|
|
0
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
PROCESSA
PHARMACEUTICALS, INC.
|
|
|
|
Date:
November 5, 2021
|
By:
|
/s/
David Young
|
|
|
David
Young
|
|
|
Chief
Executive Officer
|
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024